Əsas səhifə

Çap

Əks əlaqə

İnfo
Endoscopic pneumatic dilation versus botulinum toxin injection in the management of primary achalasia

Mündəricat

Endoscopic pneumatic dilation versus botulinum toxin injection in the management of primary achalasia

Sübutlu məlumatların xülasələri
14.07.2015 • Sonuncu dəyişiklik 14.07.2015
Editors

Pneumatic dilatation (PD) is the more effective than botulinum toxin (BTX) treatment in the long term (greater than six months) for patients with achalasia.

A Cochrane review included 7 studies with a total of 178 subjects.

There was no significant difference between pneumatic dilatation (PD) or botulinum toxin (BTX) treatment in remission within four weeks of the initial intervention; with a risk ratio of remission of 1.11 (95% CI 0.97 to 1.27). There was also no significant difference in the mean oesophageal pressures between the treatment groups; with a weighted mean difference for PD of -0.77 (95% CI -2.44 to 0.91, P = 0.37). Data on remission rates following the initial endoscopic treatment were available for three studies at six months and four studies at 12 months. At six months 46 of 57 PD participants were in remission compared to 29 of 56 in the BTX group, giving a risk ratio of 1.57 (95% CI 1.19 to 2.08, P = 0.0015); whilst at 12 months 55 of 75 PD participants were in remission compared to 27 of 72 BTX participants, with a risk ratio of 1.88 (95% CI 1.35 to 2.61, P = 0.0002). No serious adverse outcomes occurred in participants receiving BTX, whilst PD was complicated by perforation in three cases.

There was no significant difference in remission between pneumatic dilatation (PD) or botulinum toxin (BTX) treatment within four weeks of the initial intervention, with a relative risk of remission of 1.15 (95% CI 0.95 to 1.38, P = 0.39) for PD compared to BTX. There was also no significant difference in the mean oesophageal pressures between the treatment groups; weighted mean difference for PD of -0.77 (95% CI -2.44 to 0.91, P = 0.37). Data on remission rates following the initial endoscopic treatment was available for two studies at six months and three studies at 12 months. At six months 22 of 29 PD participants were in remission compared to 7 of 27 in the BTX group, giving a relative risk of 2.90 (95% CI 1.48 to 5.67, P = 0.002); whilst at 12 months 33 of 47 PD participants were in remission compared to 11 of 43 BTX participants, relative risk of 2.67 (95% CI 1.58 to 4.52, P = 0.0002). No serious adverse outcomes occurred in participants receiving BTX, whilst PD was complicated by perforation in three cases. A systematic review including 5 controlled studies (number of participants not stated) and 48 uncontrolled studies with a total of 3,549 subjects was abstracted in DARE. A single controlled trial found that Heller myotomy via thoracotomy was superior to pneumatic dilatation (95% vs 51% nearly complete symptom resolution) after 5 years. Pneumatic dilatation was more effective than botulinum toxin in one trial. A placebo-controlled trial showed that nifedipine was effective in reducing symptoms and in lowering oesophageal sphincter pressure.

Comment: The quality of evidence is downgraded by imprecise results (few patients).

Ədəbiyyat

  1. Spiess AE, Kahrilas PJ. Treating achalasia: from whalebone to laparoscope. JAMA 1998 Aug 19;280(7):638-42.
  2. Leyden JE, Moss AC, MacMathuna P. Endoscopic pneumatic dilation versus botulinum toxin injection in the management of primary achalasia. Cochrane Database Syst Rev 2014;12():CD005046.